Krebs Biochemicals & Industries Limited

CIN: L24110AP1991PLC103912



12th October, 2018

To, The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai- 400051.

The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

Dear Sir/Madam,

Sub: Investor Grievances Report for the quarter ended 30th September, 2018 Ref: Reg. 13(3) of SEBI (LODR) Regulations, 2015

We refer to the above captioned subject, we herewith submit you the report on investor grievances for the quarter ended 30th September, 2018 as required under Reg. 13(3) of SEBI

(LODR) Regulations, 2015.

Particulars	Complaints pending at the beginning of the period ended 30-06-2018	Complaints received during the period ended 30-09-2018	Complaints disposed and resolved at the end of the quarter	Complaints unresolved at the end of the quarter
Non-receipt of Share certificates	0	0	0	0
Non-receipt of duplicate share certificates	0	0	0	0
Non-receipt of Annual Report	0	0	0	0
Transmission of Securities	0	0	0	0
Non-receipt of dividend Warrants	0	0	0	0
Complaints registered in SCORES/Stock Exchanges	1	0	1	0
Total	1	0	1	0

Kindly take the same into your records.

Thanking you

Yours Faithfully,

For Krebs Biochemicals & Industries Limited

Haritha Varanasi Company Secretary

Regd. Office: Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031

Corporate Office: 8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034

Tel: 040-66808040 E-mail: marketing@krebsbiochem.com Website: www.krebsbiochem.com